Abstract
Aberrant activation of Wnt signaling triggered by mutations in either Adenomatous Polyposis Coli (APC) or CTNNB1 (β-catenin) is a hallmark of colorectal cancers (CRC). As part of a program to develop epigenetic regulators for cancer therapy, we developed carboxamide-substituted benzhydryl amines (CBAs) bearing either aryl or heteroaryl groups that selectively targeted histone lysine demethylases (KDMs) and functioned as inhibitors of the Wnt pathway. A biotinylated variant of N-((5-chloro-8-hydroxyquinolin-7-yl) (4-(diethylamino)phenyl)-methyl)butyramide (CBA-1) identified KDM3A as a binding partner. KDM3A is a Jumonji (JmjC) domain-containing demethylase that is significantly upregulated in CRC. KDM3A regulates the demethylation of histone H3's lysine 9 (H3K9Me2), a repressive marker for transcription. Inhibiting KDM3 increased H3K9Me2 levels, repressed Wnt target genes, and curtailed in vitro CRC cell proliferation. CBA-1 also exhibited in vivo inhibition of Wnt signaling in a zebrafish model without displaying in vivo toxicity.
Original language | English |
---|---|
Article number | 101795 |
Journal | iScience |
Volume | 23 |
Issue number | 12 |
DOIs | |
State | Published - Dec 18 2020 |
Bibliographical note
Publisher Copyright:© 2020 The Author(s)
Funding
We are grateful to Professor Randall Moon for the Super 8× TOPFlash and 8× FOPFlash plasmids and Professor Tianyan Gao for mouse colon cancer organoids. C.L. and D.S.W. were supported by NIH R01 CA172379 from the National Institutes of Health and by NIH UL1 TR000117 from the National Institutes of Health to the University of Kentucky's Center for Clinical and Translational Science. D.S.W. was also supported in part by the Office of the Dean of the College of Medicine, the Center for Pharmaceutical Research and Innovation in the College of Pharmacy, the Department of Defense (DoD) Prostate Cancer Research Program Award W81XWH-16-1-0635 [Grant Log# PC150326P2 ], and NIH P30 RR020171 from the National Institute of General Medical Sciences to L. Hersh. V.M.S. was supported by grant IRG 16-182-28 from the American Cancer Society . J.S.B. and M.G.H. are supported by NIH R37 CA227656 and T32 CA165990 , respectively. This study is also supported by Markey Cancer Center ( P30 CA177558 ). We are grateful to Professor Randall Moon for the Super 8× TOPFlash and 8× FOPFlash plasmids and Professor Tianyan Gao for mouse colon cancer organoids. C.L. and D.S.W. were supported by NIH R01 CA172379 from the National Institutes of Health and by NIH UL1 TR000117 from the National Institutes of Health to the University of Kentucky's Center for Clinical and Translational Science. D.S.W. was also supported in part by the Office of the Dean of the College of Medicine, the Center for Pharmaceutical Research and Innovation in the College of Pharmacy, the Department of Defense (DoD) Prostate Cancer Research Program Award W81XWH-16-1-0635 [Grant Log# PC150326P2], and NIH P30 RR020171 from the National Institute of General Medical Sciences to L. Hersh. V.M.S. was supported by grant IRG 16-182-28 from the American Cancer Society. J.S.B. and M.G.H. are supported by NIH R37 CA227656 and T32 CA165990, respectively. This study is also supported by Markey Cancer Center (P30 CA177558). Conceptualization, C.L. and D.S.W.; Methodology, W.Z. V.M.S. Y.X. T.Y. and M.G.H.; Data Analysis, W.Z. V.M.S. J.S.B. and C.-G.Z.; Supervision, C.L. D.S.W. J.S.B. and C.-G.Z.; Writing, C.L. and D.S.W. C.L. and D.S.W. have partial ownership in a for-profit venture, Epionc, Inc. that seeks to develop small-molecule inhibitors for cancer treatment. In accord with University of Kentucky policies, C.L. and D.S.W. have disclosed this work to the University of Kentucky's Intellectual Property Committee and to a Conflict of Interest Oversight Committee in accord with University of Kentucky policies.
Funders | Funder number |
---|---|
Center for Pharmaceutical Research and Innovation in the College of Pharmacy | |
University of Kentucky policies | |
National Institutes of Health (NIH) | R01 CA172379, UL1 TR000117 |
U.S. Department of Defense | W81XWH-16-1-0635, P30 RR020171, PC150326P2 |
American Cancer Society | R37 CA227656, T32 CA165990 |
National Institute of General Medical Sciences | IRG 16-182-28 |
University of Kentucky | |
University of Kentucky Markey Cancer Center | P30 CA177558 |
Keywords
- Biochemical Mechanism
- Biochemistry
- Biological Sciences
ASJC Scopus subject areas
- General